Filing Flows › ResMed (RMD) › Q3 FY25
ResMed (RMD) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Apr 24, 2025
ResMed (RMD) reported revenue of $1.3B for the third quarter fiscal 2025 (Q3 FY25), +8% from a year earlier and +0.8% from the quarter before. Operating margin was 33.0%, net earnings $365M (28.3% of revenue).
ResMed, Q3 FY25: revenue $1.3B (+8% year over year), operating margin 33.0%, net earnings $365M, operating cash flow $579M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3B | +0.8% | +8% |
| Gross profit | $766M | +2% | +11% |
| Operating profit | $426M | +2% | +14% |
| Net earnings | $365M | +6% | +21% |
| Operating cash flow | $579M | +87% | +44% |
| Free cash flow | $558M | +94% | +46% |
What changed
Revenue was $1.3B in Q3 FY25, up 8% year over year and up 1% from the previous quarter. Total Sleep and Breathing Health was the largest line at 88% of revenue. Total Sleep and Breathing Health added $0.08B year over year (up 8%), 86% of the total change.
Gross margin was 59.3%, up 1.5 points from a year earlier. Operating profit was $0.43B, a 33.0% margin (up 1.7 points year over year). Of the extra revenue versus a year earlier, 55% reached operating profit, above the 31% margin then. Operating expenses grew 7% against revenue growth of 8%. Net earnings were $0.37B, up 21% year over year. The effective tax rate was 12.6%.
Operating cash flow was $0.58B (up 44% year over year), 159% of net earnings. Non-cash charges added back $0.04B of depreciation and amortization and $0.02B of share-based compensation. Working capital and other items added $0.15B. Capital expenditures of $0.02B left free cash flow of $0.56B.
Questions
What was ResMed's revenue in the third quarter fiscal 2025?
ResMed (RMD) reported revenue of $1.3B for the third quarter fiscal 2025 (Q3 FY25), +8% from a year earlier and +0.8% from the quarter before.
Was ResMed profitable in the third quarter fiscal 2025?
Operating profit was $426M (33.0% of revenue) and net earnings $365M.
Source: ResMed 10-Q on SEC EDGAR.